PHASE I CLINICAL & PHARMACOKINETIC STUDY OF RHIZOXIN AS A 72 HOUR INFUSION

I期临床

• 批准号: 6245580
• 负责人: GINI F. FLEMING
• 金额: $ 3.72万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-06 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6245580
• 关键词: antimitotics; blood chemistry; clinical research; clinical trial phase I; dosage; drug screening /evaluation; human subject; pharmacokinetics

This Phase I Study will determine the maximum tolerated dose and associated toxicities of a 72-hour continuous infusion of Rhizoxin, a new anitmitotic agent. Plasma levels will be obtained and correlated with toxicities such as myelosuppression and mucositis.

本I期研究将确定最大耐受剂量， 一种新的抗真菌药物， 抗有丝分裂剂。 将获得血浆水平，并与 毒性如骨髓抑制和粘膜炎。